IP Library › Granted Patent US 10,030,044

Granted Patent B2

US 10,030,044 · App. 15/039,176 · Granted Jul 24, 2018

Nucleotides for the treatment of liver cancer

Inventors: Cyril B. Dousson (Canet, FR); David Dukhan (Saint Gely du Fesc, FR); Christophe Claude Parsy (Jacou, FR)

C07H19/207 A61K31/7076 C07H19/06 C07H19/10 C07H19/16 C07H19/20 A61K31/706 A61K31/708 A61K31/7052 A61K31/7064 A61K31/7068 A61K31/7072

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,030,044
App. No.: 15/039,176
Granted: Jul 24, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z 1 , Z 2 , Z 3 , Z 4 , V, W, X, Ar, R 1 and R 2 are as described herein.

Claims (164)

1. A compound according to Formula I or VI:

or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Base 2 is

or a tautomeric form thereof;

R 4 is sulfanyl, —NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , or —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ ;

R 7 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

wherein R 1′ and R 2′ at each occurrence are independently hydrogen, C 1 to C 10 unsubstituted alkyl, C 1 to C 10 substituted alkyl, C 2 -C 11 unsubstituted alkenyl, C 2 -C 11 substituted alkenyl, C 2 -C 11 unsubstituted alkynyl, C 2 -C 11 substituted alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl;

R 7A is hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1A R 2A ;

wherein R 1A and R 2A at each occurrence are independently C 1 to C 10 unsubstituted alkyl, C 1 to C 10 substituted alkyl, C 2 -C 11 unsubstituted alkenyl, C 2 -C 11 substituted alkenyl, C 2 -C 11 unsubstituted alkynyl, C 2 -C 11 substituted alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl;

X is O or S;

W is O or S;

Ar is aryl or heteroaryl;

R 1 is hydrogen, alkyl, arylalkyl, or heteroarylalkyl;

R 2 is alkyl, arylalkyl, heterocycloalkyl, carboxylalkyl, heteroarylalkyl, aminoalkyl, hydroxylalkyl, aminoiminoaminoalkyl, aminocarbonylalkyl, sulfanylalkyl, carbamoylalkyl, alkylsulfanylalkyl, or hydroxylarylalkyl;

Z 1 is hydrogen, hydroxyl, halogen, or cyano;

Z 2 is hydrogen, hydroxyl, or halogen;

Z 3 is hydrogen;

Z 4 is hydroxyl, halogen, amino, or alkynyl;

V is hydrogen, halogen, or amino;

subject to the proviso that when, in Formula I: Z 1 is hydrogen, then: either V is halogen; or Z 4 is halogen, amino, or alkynyl.

2. The compound of claim 1 according to Formula Ia or Ib:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Base 2 is

or a tautomeric form thereof;

Ar is aryl or heteroaryl;

R 1 is hydrogen, C 1 to C 10 unsubstituted alkyl, C 1 to C 10 substituted alkyl, —(C 1 to C 10 unsubstituted alkyl)-aryl, —(C 1 to C 10 substituted alkyl)-aryl, —(C 1 to C 10 unsubstituted alkyl)-heteroaryl, or —(C 1 to C 10 substituted alkyl)-heteroaryl;

R 2 is C 1 to C 10 unsubstituted alkyl, C 1 to C 10 substituted alkyl, —(C 1 to C 10 unsubstituted alkyl)-aryl, —(C 1 to C 10 substituted alkyl)-aryl, —(C 1 to C 10 unsubstituted alkyl)-heterocyclo, —(C 1 to C 10 substituted alkyl)-heterocyclo, —(C 1 to C 10 unsubstituted alkyl)-C(O)OH, —(C 1 to C 10 substituted alkyl)-C(O)OH, —(C 1 to C 10 unsubstituted alkyl)-heteroaryl, —(C 1 to C 10 substituted alkyl)-heteroaryl, —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-OH, —(C 1 to C 10 substituted alkyl)-OH, —(C 1 to C 10 unsubstituted alkyl)-NR 1′ —C(NH)—NR 1′ R 2′ , —(C 1 to C 10 substituted alkyl)-NR 1′ —C(NH)—NR 1′ R 2 , —(C 1 to C 10 unsubstituted alkyl)-C(O)—NR 1′ R 2′ , —(C 1 to C 10 substituted alkyl)-C(O)—NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-SH, —(C 1 to C 10 substituted alkyl)-SH, —(C 1 to C 10 unsubstituted alkyl)-C(O)—NR 1′ R 2′ , —(C 1 to C 10 substituted alkyl)-C(O)—NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-S—(C 1 to C 10 unsubstituted alkyl), —(C 1 to C 10 unsubstituted alkyl)-S—(C 1 to C 10 substituted alkyl), —(C 1 to C 10 substituted alkyl)-S—(C 1 to C 10 unsubstituted alkyl), —(C 1 to C 10 substituted alkyl)-S—(C 1 to C 10 substituted alkyl), —(C 1 to C 10 unsubstituted alkyl)-aryl-OH, or —(C 1 to C 10 substituted alkyl)-aryl-OH;

Z 1 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or cyano;

Z 2 is hydrogen, hydroxyl, chloro, bromo, fluoro, or iodo;

Z 4 is hydroxyl, chloro, bromo, fluoro, iodo, —NR 1′ R 2′ , C 2 -C 11 unsubstituted alkynyl, or C 2 -C 11 substituted alkynyl;

V is hydrogen, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

R 1′ and R 2′ at each occurrence are independently hydrogen, C 1 to C 10 unsubstituted alkyl, C 1 to C 10 substituted alkyl, C 2 -C 11 unsubstituted alkenyl, C 2 -C 11 substituted alkenyl, C 2 -C 11 unsubstituted alkynyl, C 2 -C 11 substituted alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl;

aryl at each occurrence is independently C 6 -C 12 unsubstituted aryl; or C 6 -C 12 aryl substituted with one or more fluoro, chloro, bromo, iodo, methyl, CF 3 , CCl 3 , CFCl 2 , CF 2 Cl, ethyl, CH 2 CF 3 , CF 2 CF 3 , propyl, isopropyl, butyl, isobutyl, secbutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hydroxyl, —NH 2 , —NH—(C 1 to C 10 unsubstituted alkyl), —NH—(C 1 to C 10 substituted alkyl), —NH-aryl, —NH—(C 3 -C 15 cycloalkyl), methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, oxo, epoxy, hydroxyl, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate;

cycloalkyl at each occurrence is independently C 3 -C 15 unsubstituted cycloalkyl or C 3 -C 15 cycloalkyl substituted with fluoro, chloro, bromo, iodo, oxo, epoxy, hydroxyl, carbonyl, sulfanyl, —NH 2 , methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate;

heterocyclo at each occurrence is independently a monovalent monocyclic or multicyclic non-aromatic that contains at least one non-aromatic ring containing one or more heteroatoms independently selected from O, S, and N in the ring, wherein heterocyclo is bonded through the non-aromatic ring, and wherein heterocyclo has from three to twenty ring atoms;

heteroaryl at each occurrence is independently a monovalent monocyclic or multicyclic aromatic that contains at least one aromatic ring containing one or more heteroatoms independently selected from O, S, and N in the ring, wherein heteroaryl is bonded through the aromatic ring, wherein the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom, and wherein heteroaryl has from five to twenty ring atoms;

substituted alkenyl at each occurrence is independently a straight-chained or branched olefinically unsaturated hydrocarbon having at least one site of olefinic unsaturation substituted with fluoro, chloro, bromo, iodo, oxo, epoxy, hydroxyl, carbonyl, sulfanyl, —NH 2 , methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate;

substituted alkynyl at each occurrence is independently a straight-chained or branched acetylenically unsaturated hydrocarbon having at least one site of alkynyl unsaturation substituted with fluoro, chloro, bromo, iodo, oxo, epoxy, hydroxyl, carbonyl, sulfanyl, —NH 2 , methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate;

substituted alkyl at each occurrence is independently alkyl substituted with fluoro, chloro, bromo, iodo, oxo, epoxy, hydroxyl, carbonyl, sulfanyl, —NH 2 , methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; and

subject to the proviso that when, in Formula I: Z 1 is hydrogen, then: either V is chloro, bromo, fluoro, iodo; or Z 4 is chloro, bromo, fluoro, iodo, —NR 1′ R 2′ , C 2 -C 11 unsubstituted alkynyl, or C 2 -C 11 substituted alkynyl.

4. The compound of claim 1 according to Formula II, IIa or IIb:

or a pharmaceutically acceptable salt thereof, wherein Z 1 is hydrogen, hydroxyl, halogen, or cyano.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Ar is aryl or heteroaryl;

Z 1 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or cyano;

Z 2 is hydrogen, hydroxyl, chloro, bromo, fluoro, or iodo;

R 4 is sulfanyl, —NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , or —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ ;

R 7 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

subject to the proviso that when, in Formula II: Z 1 is hydrogen, then: either Z 4 is chloro, bromo, fluoro, iodo, —NR 1′ R 2′ , C 2 -C 11 unsubstituted alkynyl, or C 2 -C 11 substituted alkynyl.

6. The compound of claim 1 according to Formula III, IIIa or IIIb:

or a pharmaceutically acceptable salt thereof, wherein Z 4 is fluoro, amino, or alkynyl.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Ar is aryl or heteroaryl;

Z 4 is fluoro, —NR 1′ R 2′ , C 2 -C 11 unsubstituted alkynyl, or C 2 -C 11 substituted alkynyl;

R 4 is sulfanyl, —NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , or —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ ;

R 7 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

8. The compound of claim 1 according to Formula IV, IVa or IVb:

or a pharmaceutically acceptable salt thereof, wherein Z 2 is hydrogen or hydroxyl.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Ar is aryl or heteroaryl;

R 4 is sulfanyl, —NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , or —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ ;

R 7 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

10. The compound of claim 1 according to Formula V, Va or Vb:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein:

Base 1 is

or a tautomeric form thereof;

Ar is aryl or heteroaryl;

R 4 is sulfanyl, —NR 1′ R 2′ , —(C 1 to C 10 unsubstituted alkyl)-NR 1′ R 2′ , or —(C 1 to C 10 substituted alkyl)-NR 1′ R 2′ ;

R 7 is hydrogen, hydroxyl, chloro, bromo, fluoro, iodo, or —NR 1′ R 2′ ;

12. The compound of claim 1 , wherein Z 1 is —OH; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —H.

13. The compound of claim 1 , wherein Z 1 is —OH; Z 2 is —F; Z 3 is —H; Z 4 is —OH; and V is —H.

14. The compound of any of claim 1 , wherein Z 1 is —F; Z 2 is —OH; Z 3 is —H; Z 4 is —H; and V is —H.

15. The compound of any of claim 1 , wherein Z 1 is —F; Z 2 is —F; Z 3 is —H; Z 4 is —OH; and V is —H.

16. The compound of any of claim 1 , wherein Z 1 is —F; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —H.

17. The compound of any of claim 1 , wherein Z 1 is —F; Z 2 is —Cl; Z 3 is —H; Z 4 is —OH; and V is —H.

18. The compound of any of claim 1 , wherein Z 1 is —Cl; Z 2 is —Cl; Z 3 is —H; Z 4 is —OH; and V is —H.

19. The compound of any of claim 1 , wherein Z 1 is —Cl; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —H.

20. The compound of any of claim 1 , wherein Z 1 is —Cl; Z 2 is —F; Z 3 is —H; Z 4 is —OH; and V is —H.

21. The compound of any of claim 1 , wherein Z 1 is —F; Z 2 is —F; Z 3 is —H; Z 4 is —OH; and V is —H.

22. The compound of any of claim 1 , wherein Z 1 is —CN; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —H.

23. The compound of any of claim 1 , wherein Z 1 is —H; Z 2 is —H; Z 3 is —H; Z 4 is —C≡CH; and V is —H.

24. The compound of any of claim 1 , wherein Z 1 is —H; Z 2 is —H; Z 3 is —H; Z 4 is —F; and V is —H.

25. The compound of any of claim 1 , wherein Z 1 is —H; Z 2 is —H; Z 3 is —H; Z 4 is —NH 2 ; and V is —H.

26. The compound of any of claim 1 , wherein Z 1 is —H; Z 2 is —F; Z 3 is —H; Z 4 is —OH; and V is —F.

27. The compound of any of claim 1 , wherein Z 1 is —CN; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —H.

28. The compound of any of claim 1 , wherein Z 1 is —CN; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and V is —NH 2 .

29. The compound of claim 1 , wherein Z 1 is —H; Z 2 is —H; Z 3 is —H; Z 4 is —OH; and Base 1 is selected from

and Base 2 is selected from

30. The compound of claim 1 , wherein Z 1 is —H; Z 2 is —OH; Z 3 is —H; Z 4 is —OH; and Base 1 and Base 2 are selected from

31. The compound of any of claim 1 , wherein R 2 is methyl.

32. The compound of any of claim 1 , wherein Ar is phenyl.

33. The compound of any of claim 1 , wherein R 1 is isopropyl.

34. The compound of claim 1 , wherein:

Base 1 is

or a tautomeric form thereof;

Base 2 is

or a tautomeric form thereof;

R 4 is sulfanyl, amino, or aminoalkyl;

R 7 is hydrogen, hydroxyl, halogen, or amino; and

R 7A is hydroxyl or halogen.

35. The compound of any of claim 1 , wherein the group N-linked to the phosphorus atom is a D-amino acid residue, or a derivative thereof.

36. The compound of any of claim 1 , with R P stereochemistry.

37. The compound of any of claim 1 , with S P stereochemistry.

38. The compound of any of claim 1 , that is isolated.

39. A pharmaceutical composition comprising the compound of claim 1 and-a pharmaceutically acceptable excipient, carrier or diluent.

40. The pharmaceutical composition of claim 39 , wherein the composition is an oral formulation.

41. A method for the treatment of a subject with liver cancer in a host in need thereof, comprising the administration of an effective amount of a compound of claim 1 .

42. The method of claim 41 , wherein the host is a human.

43. The method of claim 41 wherein the liver cancer is hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer.

44. The method of claim 41 , wherein the administration directs a substantial amount of the compound, or pharmaceutically acceptable salt thereof, to a liver of the subject.

45. A compound, or a pharmaceutically acceptable salt thereof, said compound selected from:

46. A compound, or a pharmaceutically acceptable salt thereof, said compound selected from:

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2016

From: DOUSSON, CYRIL B.; DUKHAN, DAVID; PARSY, CHRISTOPHE CLAUDE

To: IDENIX PHARMACEUTICALS LLC

Reel/Frame 040063/0024 →

Continuity (2)

Provisional Application 61909941 · Nov 27, 2013

Related Publication 20170029456A1 · Feb 2, 2017